Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).

被引：0

作者：

Tam, Eric Leon

Iberri, David Joseph

Liedtke, Michaela

Muffly, Lori S.

Shiraz, Parveen

Frank, Matthew Joshua

Lowsky, Robert

Rezvani, Andrew

Negrin, Robert

Meyer, Everett

Arai, Sally

Johnston, Laura J.

Shizuru, Judith

Weng, Wen-Kai

Miklos, David Bernard

Sidana, Surbhi

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Stanford, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20557

引用

页数：2